Letters
18 March 2025

Cutting-edge insights: LC-OCT and 5% cyclosporine for early lichen sclerosus treatment

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
192
Views
141
Downloads

Authors

Dear Editor,

Atrophic lichen sclerosus (ALS) is a chronic inflammatory dermatosis with significant morbidity, primarily affecting genital areas. The disease is often misdiagnosed or underdiagnosed, resulting in delayed treatment and progression to atrophic stages and permanent scars. While corticosteroids remain the first-line treatment, their long-term use may lead to adverse effects such as skin atrophy, prompting the need for alternative therapies. Cyclosporine, a calcineurin inhibitor, has shown efficacy in managing immune-mediated skin diseases and is delivered effectively through the Pentravan® vehicle. [...]

Altmetrics

Downloads

Download data is not yet available.

Citations

Romisher A, Ross CL, Ross NA. Lichen Sclerosus in Perspective. Skinmed 2024;22:253-9.
Ch'en PY, Lio PA. Nonsteroidal Approaches for Atopic Dermatitis®: A Clinical Update. Dermatitis 2024;35:596-604. DOI: https://doi.org/10.1089/derm.2023.0373
Giorgio CMR, Briatico G, Licata G, et al. Topical cyclosporine 5% cream in Zoon's balanitis resistant to other therapies: A case report. Dermatol Ther 2021;34:e14807. DOI: https://doi.org/10.1111/dth.14807
Cappilli S, Paradisi A, Di Stefani A, et al. Line-Field Confocal Optical Coherence Tomography: A New Skin Imaging Technique Reproducing a "Virtual Biopsy" with Evolving Clinical Applications in Dermatology. Diagnostics (Basel) 2024;14:1821. DOI: https://doi.org/10.3390/diagnostics14161821

How to Cite



Cutting-edge insights: LC-OCT and 5% cyclosporine for early lichen sclerosus treatment. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10279